(HLVX) Hillevax - Ratings and Ratios

HilleVax, Inc. (NASDAQ:HLVX), a clinical-stage biopharmaceutical company, specializes in the development and commercialization of innovative vaccines. Its lead candidate, HIL-214, is a virus-like particle (VLP)-based vaccine designed to prevent moderate-to-severe acute gastroenteritis caused by norovirus, a highly contagious pathogen affecting millions globally. The company, rebranded from MokshaCo, Inc. in February 2021, leverages VLP technology for its potential to induce strong immune responses without the need for live virus, enhancing safety and efficacy. Founded in 2019 and headquartered in Boston, Massachusetts, HilleVax is strategically positioned in a hub for biotech innovation, facilitating collaborations and access to cutting-edge research.

From a technical perspective, HLVX is currently trading at $1.78 with a 20-day average volume of 179,327 shares. The stock is below its 20-day and 50-day simple moving averages (SMAs) of $1.83 and $1.91, respectively, and significantly below its 200-day SMA of $3.95. The Average True Range (ATR) of 0.08 indicates low volatility. On the fundamental side, HilleVax has a market capitalization of $89.15 million, with a price-to-book (P/B) ratio of 0.48, suggesting the stock is trading below its book value. The return on equity (RoE) of -81.55% reflects significant losses, likely due to research and development investments.

3-Month Forecast: Based on the provided data, HLVX is expected to face downward pressure. The stocks price is below key SMAs, indicating a bearish trend. With low volatility (ATR of 0.08), significant price swings are unlikely. Fundamentally, the companys negative RoE and lack of profitability suggest ongoing challenges. Without positive catalysts, such as successful clinical trial results or partnerships, HLVX may continue its decline or remain range-bound. Investors should monitor for potential upside triggers, but the current outlook remains cautious.